Location: Barcelona, Spain – 3 days working from the office and 2 days working from home.
Alexion, AstraZeneca Rare Disease, is expanding its leadership in transformative rare disease therapies beyond complement biology by advancing innovative therapies across metabolic, bone metabolism and endocrine disorders.
Building on its leadership in hypophosphatasia (HPP) and expanding into conditions such as hypoparathyroidism (HPT), the company with the Enboparatide asset combines cutting‑edge science with strong value and access strategies to improve outcomes for patients living with rare metabolic and endocrine diseases.
To achieve this ambition and timely sustainable market access & pricing across our global geography footprint requires enhancing our Global Access-Pricing capabilities by recruiting a global Access & Pricing lead for Endocrinology.